Dr Ralf Hoffmann
- Honorary Senior Lecturer (School of Psychology & Neuroscience)
email:
Ralf.Hoffmann@glasgow.ac.uk
FBLS - Integrated Biology, West Medical Building
Publications
2023
Gulliver, C., Baillie, G. S. and Hoffmann, R. (2023) Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region. Future Science OA, (doi: 10.2144/fsoa-2023-0064) (Early Online Publication)
Gulliver, C., Huss, S., Semjonow, A., Baillie, G. S. and Hoffmann, R. (2023) The CAPRA&PDE4D5/7/9 prognostic model is significantly associated to adverse post-surgical pathology outcomes. Cancers, 15(1), 262. (doi: 10.3390/cancers15010262) (PMID:36612262) (PMCID:PMC9818961)
2022
Gulliver, C., Hoffmann, R. and Baillie, G. S. (2022) Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer. International Journal of Biochemistry and Cell Biology, 147, 106230. (doi: 10.1016/j.biocel.2022.106230) (PMID:35609768)
2021
Baillie, G. S. , Gulliver, C. and Hoffmann, R. (2021) The enigmatic helicase DHX9 and its association with the hallmarks of cancer. Future Science OA, 7(2), FSO650. (doi: 10.2144/fsoa-2020-0140) (PMID:33437516) (PMCID:PMC7787180)
2018
van Strijp, D. et al. (2018) The prognostic PDE4D7 score in a diagnostic biopsy prostate cancer patient cohort with longitudinal biological outcomes. Prostate Cancer, 2018, 5821616. (doi: 10.1155/2018/5821616) (PMID:30147955) (PMCID:PMC6083737)
2015
Byrne, A. M., Elliott, C. , Hoffmann, R. and Baillie, G. S. (2015) The activity of cAMP-Phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus. FEBS Letters, 589(6), pp. 750-755. (doi: 10.1016/j.febslet.2015.02.004) (PMID:25680530) (PMCID:PMC4346272)
2014
Henderson, D.J.P., Byrne, A., Dulla, K., Jenster, G., Hoffmann, R., Baillie, G.S. and Houslay, M.D. (2014) The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells. British Journal of Cancer, 110(5), pp. 1278-1287. (doi: 10.1038/bjc.2014.22)
Articles
Gulliver, C., Baillie, G. S. and Hoffmann, R. (2023) Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region. Future Science OA, (doi: 10.2144/fsoa-2023-0064) (Early Online Publication)
Gulliver, C., Huss, S., Semjonow, A., Baillie, G. S. and Hoffmann, R. (2023) The CAPRA&PDE4D5/7/9 prognostic model is significantly associated to adverse post-surgical pathology outcomes. Cancers, 15(1), 262. (doi: 10.3390/cancers15010262) (PMID:36612262) (PMCID:PMC9818961)
Gulliver, C., Hoffmann, R. and Baillie, G. S. (2022) Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer. International Journal of Biochemistry and Cell Biology, 147, 106230. (doi: 10.1016/j.biocel.2022.106230) (PMID:35609768)
Baillie, G. S. , Gulliver, C. and Hoffmann, R. (2021) The enigmatic helicase DHX9 and its association with the hallmarks of cancer. Future Science OA, 7(2), FSO650. (doi: 10.2144/fsoa-2020-0140) (PMID:33437516) (PMCID:PMC7787180)
van Strijp, D. et al. (2018) The prognostic PDE4D7 score in a diagnostic biopsy prostate cancer patient cohort with longitudinal biological outcomes. Prostate Cancer, 2018, 5821616. (doi: 10.1155/2018/5821616) (PMID:30147955) (PMCID:PMC6083737)
Byrne, A. M., Elliott, C. , Hoffmann, R. and Baillie, G. S. (2015) The activity of cAMP-Phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus. FEBS Letters, 589(6), pp. 750-755. (doi: 10.1016/j.febslet.2015.02.004) (PMID:25680530) (PMCID:PMC4346272)
Henderson, D.J.P., Byrne, A., Dulla, K., Jenster, G., Hoffmann, R., Baillie, G.S. and Houslay, M.D. (2014) The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells. British Journal of Cancer, 110(5), pp. 1278-1287. (doi: 10.1038/bjc.2014.22)